Sulanda (surufatinib)

Increasing evidence suggests that a subset of CCA patients can benefit from multiple tyrosine kinase inhibitors (mTKIs) such as surufatinib...Furthermore, cancer-associated fibroblasts (CAFs) were identified as the major source of IGF1 in CCA microenvironment, essential for IGF1R-driven tumor progression.In summary, the PTPN9-IGF1R axis plays a pivotal role in modulating mTKI sensitivity and tumor progression in CCA. This axis serves as a promising biomarker for identifying potential mTKI beneficiaries and represents a potential therapeutic target to enhance mTKI efficacy and overcome resistance.

From August 2019 to October 2020, he received long-acting octreotide and transarterial chemoembolization (TACE), achieving stable disease...In September 2022, oral surufatinib was initiated but paused in September 2023 due to adverse effects...This case demonstrates that everolimus can induce SSTR re-expression in advanced, SSTR-negative pNETs, offering new therapeutic possibilities. The "induction plus re-evaluation" approach could guide personalized treatment strategies in late-stage pNETs, although further studies are needed to validate this approach.

Surufatinib plus paclitaxel showed promising efficacy and manageable safety as second-line treatment for advanced gastric cancer, especially in patients who had failed prior immunotherapy.

We report a case of a 59-year-old woman with stage IVA GBC who was unable to tolerate first-line gemcitabine and cisplatin due to severe adverse effects...Based on a multidisciplinary team assessment, she received camrelizumab (PD-1 inhibitor) plus apatinib (VEGFR2 inhibitor)...Following isolated cervical lymph node metastasis, combination therapy with camrelizumab and surufatinib resulted in complete remission...This case highlights the promising potential of targeted therapy and immunotherapy in converting unresectable GBC to operable disease and achieving durable remission, even in patients lacking classic immunotherapy biomarkers. Personalized, non-chemotherapy-based strategies may offer viable alternatives for selected patients.

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and limited first-line treatments. In the NASCA group, enrichment of CD8+ and CD8+PD-1+ cells, a high baseline M1/M2 macrophage ratio, and a reduction in CA19-9 levels at weeks 6 and 12 were associated with improved PFS compared to patients without these features. The NASCA regimen showed promising efficacy with tolerable safety relative to nab-paclitaxel and gemcitabine for locally advanced or metastatic PDAC.

The patient participated in the "randomized, open, multicentre phase III clinical study to evaluate the efficacy and safety of solantinib combined with toripalimab versus FOLFIRI as second-line treatment for advanced neuroendocrine carcinoma", and the efficacy of the FOLFIRI regimen was evaluated after 4 cycles of chemotherapy for PD. The best results were a partial response (PR) and a PFS of up to 15.1 months. This case confirmed the efficacy of ICI therapy against TMB-H lung large-cell neuroendocrine carcinoma, suggesting that the immune microenvironment and TMB analysis are helpful for guiding the personalized treatment of LCNEC.

P1/2, N=36, Completed, Hutchmed | Active, not recruiting --> Completed

P2, N=32, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2025

P2, N=21, Completed, Hutchison Medipharma Limited | Recruiting --> Completed | N=60 --> 21

P4, N=30, Not yet recruiting, Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University

P2, N=65, Recruiting, Fudan University | Not yet recruiting --> Recruiting | Trial completion date: Jul 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026

P2, N=80, Recruiting, Sun Yat-sen University